Healing Human Moderate and Large Traumatic Tympanic Membrane Perforations Using Basic Fibroblast Growth Factor, 0.3% Ofloxacin Eardrops, and Gelfoam Patching

The goal of this study was to evaluate the effects of basic fibroblast growth factor (bFGF), 0.3% ofloxacin eardrops (OFLX), and Gelfoam patching on the healing of human moderate and large traumatic tympanic membrane perforations (TMPs). A prospective, quasi-randomized, controlled clinical study. A...

Full description

Saved in:
Bibliographic Details
Published inOtology & neurotology Vol. 37; no. 6; p. 735
Main Authors Lou, Zheng-Cai, Lou, Zi-Han, Liu, Ya-Chao, Chang, Jiang
Format Journal Article
LanguageEnglish
Published United States 01.07.2016
Subjects
Online AccessGet more information

Cover

Loading…
Abstract The goal of this study was to evaluate the effects of basic fibroblast growth factor (bFGF), 0.3% ofloxacin eardrops (OFLX), and Gelfoam patching on the healing of human moderate and large traumatic tympanic membrane perforations (TMPs). A prospective, quasi-randomized, controlled clinical study. A University-affiliated teaching hospital. We performed a quasi-randomized prospective analysis between January 2010 and December 2014. All patients had traumatic TMPs covering areas >25% of the entire tympanic membrane. The closure rates, closure times, hearing gains, and rates of otorrhea in patients who underwent conservative observation, Gelfoam patching, topical bFGF application, and direct application of OFLX were compared. We ultimately included 185 patients. Closure rates did not significantly differ among the four groups (p = 0.257). Post-hoc multiple comparisons also showed that the closure rates did not differ between any two groups (p > 0.083). The mean closure times were 25.6 ± 13.32, 12.3 ± 8.15, 14.3 ± 5.44, and 13.97 ± 8.82 days for the observation, bFGF, Gelfoam patch, and OFLX groups, respectively. The closure times of the four groups differed significantly (p < 0.001). Post-hoc multiple comparisons showed that the differences between the observation group and each of the other groups were significant (p < 0.001). No other between- or among-group differences were significant (p > 0.0083). The findings of this study suggest that OFLX, bFGF, and Gelfoam patching accelerated the closure of human moderate and large traumatic TMPs. Hence, treatment of human traumatic TMPs should be revisited clinically. Topical application of OFLX may be recommended, because OFLX is more easily available and convenient than bFGF or Gelfoam patch for otology outpatients.
AbstractList The goal of this study was to evaluate the effects of basic fibroblast growth factor (bFGF), 0.3% ofloxacin eardrops (OFLX), and Gelfoam patching on the healing of human moderate and large traumatic tympanic membrane perforations (TMPs). A prospective, quasi-randomized, controlled clinical study. A University-affiliated teaching hospital. We performed a quasi-randomized prospective analysis between January 2010 and December 2014. All patients had traumatic TMPs covering areas >25% of the entire tympanic membrane. The closure rates, closure times, hearing gains, and rates of otorrhea in patients who underwent conservative observation, Gelfoam patching, topical bFGF application, and direct application of OFLX were compared. We ultimately included 185 patients. Closure rates did not significantly differ among the four groups (p = 0.257). Post-hoc multiple comparisons also showed that the closure rates did not differ between any two groups (p > 0.083). The mean closure times were 25.6 ± 13.32, 12.3 ± 8.15, 14.3 ± 5.44, and 13.97 ± 8.82 days for the observation, bFGF, Gelfoam patch, and OFLX groups, respectively. The closure times of the four groups differed significantly (p < 0.001). Post-hoc multiple comparisons showed that the differences between the observation group and each of the other groups were significant (p < 0.001). No other between- or among-group differences were significant (p > 0.0083). The findings of this study suggest that OFLX, bFGF, and Gelfoam patching accelerated the closure of human moderate and large traumatic TMPs. Hence, treatment of human traumatic TMPs should be revisited clinically. Topical application of OFLX may be recommended, because OFLX is more easily available and convenient than bFGF or Gelfoam patch for otology outpatients.
Author Lou, Zheng-Cai
Liu, Ya-Chao
Lou, Zi-Han
Chang, Jiang
Author_xml – sequence: 1
  givenname: Zheng-Cai
  surname: Lou
  fullname: Lou, Zheng-Cai
  organization: Department of Otorhinolaryngology, Affiliated YiWu Hospital of Wenzhou Medical University, Yiwu City, China †Department of Clinical Medicine, No.11, Xinxiang Medical University, Xinxiang City, China ‡Department of Otolaryngology Head and Neck Surgery, No.1, Affiliated Hospital of Hebei North University, Zhangjiakou City, China §Department of Pediatric Otolaryngology, Children's Hospital of Dongguan, Dongguan City, China
– sequence: 2
  givenname: Zi-Han
  surname: Lou
  fullname: Lou, Zi-Han
– sequence: 3
  givenname: Ya-Chao
  surname: Liu
  fullname: Liu, Ya-Chao
– sequence: 4
  givenname: Jiang
  surname: Chang
  fullname: Chang, Jiang
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27295381$$D View this record in MEDLINE/PubMed
BookMark eNpNkMtOwzAQRS0Eog_4A4S8YdcUO47tZFkq2iK1ahftuhondhuU2JGdCvox_CvhJTGbO5q594w0A3RpndUI3VEypiSTj6vJekz-FSUpuUB9ypmMEk54Dw1CeO3mknF5jXqxjDPOUtpHHwsNVWkPeHGqweKVK7SHVmOwBV6CP2i89dCt2jLH23PdgO2ala6VB6vxRnvjOn_pbMC78MV5gtA5ZqXyTlUQWjz37q094hnkrfMjTMbsAa9N5d4hLy1-Bl9414TR98W5royDGm-gzY8d7QZdGaiCvv3VIdrNnrfTRbRcz1-mk2WUMx6TiBrDkliYxAgdC8E1UYIqrmSmCpECKYQSRuo8z2TMGAcgOUhGk5QmsZRddIjuf7jNSdW62De-rMGf939_ij8BH3proA
CitedBy_id crossref_primary_10_1016_j_amjoto_2020_102405
crossref_primary_10_1097_MAO_0000000000001264
crossref_primary_10_1186_s40463_020_00440_7
crossref_primary_10_1002_lary_28914
crossref_primary_10_1016_j_bjorl_2020_03_007
crossref_primary_10_1097_MAO_0000000000001265
crossref_primary_10_1177_0194599818757972
crossref_primary_10_1016_j_amjoto_2020_102399
crossref_primary_10_1016_j_amjoto_2019_02_015
crossref_primary_10_1016_j_cej_2021_129536
crossref_primary_10_1155_2021_5583046
crossref_primary_10_3390_pharmaceutics12060508
crossref_primary_10_1089_ten_tea_2016_0265
crossref_primary_10_1177_01455613241264479
crossref_primary_10_1155_2021_2366291
crossref_primary_10_3389_fnmol_2021_757441
crossref_primary_10_1017_S0022215117001001
crossref_primary_10_1017_S002221511800083X
crossref_primary_10_1097_MAO_0000000000002628
crossref_primary_10_1016_j_amjoto_2022_103650
crossref_primary_10_1007_s00405_021_06891_6
crossref_primary_10_1089_ten_teb_2020_0176
crossref_primary_10_1097_MAO_0000000000002036
crossref_primary_10_12677_acm_2024_143885
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1097/MAO.0000000000001080
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1537-4505
ExternalDocumentID 27295381
Genre Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.-D
.GJ
.Z2
0R~
123
1J1
4Q1
4Q2
4Q3
53G
5VS
AAAAV
AAHPQ
AAIQE
AAMTA
AARTV
AASCR
AASOK
AAWTL
AAYEP
ABASU
ABBUW
ABDIG
ABJNI
ABVCZ
ABXVJ
ABZAD
ABZZY
ACBNA
ACCJW
ACDDN
ACEWG
ACGFS
ACILI
ACNWC
ACWDW
ACWRI
ACXJB
ACXNZ
ADFPA
ADGGA
ADHPY
ADNKB
AE3
AE6
AEETU
AENEX
AFBFQ
AFDTB
AFUWQ
AGINI
AHQNM
AHRYX
AHVBC
AINUH
AJCLO
AJIOK
AJNWD
AJNYG
AJZMW
AKCTQ
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
BQLVK
BS7
C45
CGR
CUY
CVF
DIWNM
DU5
DUNZO
E.X
EBS
ECM
EEVPB
EIF
EJD
EX3
F2K
F2L
F2M
F2N
FCALG
FL-
FW0
GNXGY
GQDEL
H0~
HLJTE
HZ~
IKREB
IN~
IPNFZ
JF9
JG8
JK3
JK8
K8S
KD2
KMI
L-C
L7B
N4W
N9A
NPM
N~M
O9-
OAG
OAH
OCUKA
ODA
OHT
OL1
OLV
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OWU
OWV
OWX
OWY
OWZ
OXXIT
R58
RIG
RLZ
S4R
S4S
T8P
TEORI
TSPGW
V2I
VVN
W3M
WOQ
WOW
X3V
X3W
XXN
XYM
ZFV
ZGI
ZZMQN
ID FETCH-LOGICAL-c3520-1ff3426f4f6e2665e0b61b5b79bd68a0d6b6f7ecc972335aa0ca7314814277342
IngestDate Thu Apr 03 07:01:19 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3520-1ff3426f4f6e2665e0b61b5b79bd68a0d6b6f7ecc972335aa0ca7314814277342
PMID 27295381
ParticipantIDs pubmed_primary_27295381
PublicationCentury 2000
PublicationDate 2016-07-00
PublicationDateYYYYMMDD 2016-07-01
PublicationDate_xml – month: 07
  year: 2016
  text: 2016-07-00
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Otology & neurotology
PublicationTitleAlternate Otol Neurotol
PublicationYear 2016
References 27755460 - Otol Neurotol. 2016 Dec;37(10 ):1680
27755459 - Otol Neurotol. 2016 Dec;37(10 ):1679-1680
References_xml – reference: 27755459 - Otol Neurotol. 2016 Dec;37(10 ):1679-1680
– reference: 27755460 - Otol Neurotol. 2016 Dec;37(10 ):1680
SSID ssj0017357
Score 2.2765598
Snippet The goal of this study was to evaluate the effects of basic fibroblast growth factor (bFGF), 0.3% ofloxacin eardrops (OFLX), and Gelfoam patching on the...
SourceID pubmed
SourceType Index Database
StartPage 735
SubjectTerms Adult
Anti-Bacterial Agents - therapeutic use
Female
Fibroblast Growth Factor 2 - therapeutic use
Gelatin Sponge, Absorbable - therapeutic use
Humans
Male
Middle Aged
Ofloxacin - therapeutic use
Prospective Studies
Treatment Outcome
Tympanic Membrane - drug effects
Tympanic Membrane Perforation - drug therapy
Wound Healing - drug effects
Young Adult
Title Healing Human Moderate and Large Traumatic Tympanic Membrane Perforations Using Basic Fibroblast Growth Factor, 0.3% Ofloxacin Eardrops, and Gelfoam Patching
URI https://www.ncbi.nlm.nih.gov/pubmed/27295381
Volume 37
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1bb9MwFMetbkiIFzTujIv8AE9ZIPe0j6NaqdBKeeik8TTZib1WWpMJpRrwXfZt9sH4H9vpQhni0ococtokyvnVOcc-52_GXiUqyQd9gdgkkqWfqCz0he5LX8PWcdlPZRJTofDkYzY-Sj4cp8e93lUna2nVyDfF9xvrSv7HqmiDXalK9h8suz4pGrAP-2ILC2P7VzamGiIK9e1IvFnWDK6jmQ84pAxvki5fWU3W2Tf632NnopYIkOFafjKJ7S4TzmYOvBOwmTdCBF1LeNUNjUxdNHNvJOzQ_tBD9P06Sr2pPqu_imJReQcg7EttZxPouu_Vma7FkqT_TZZm1_mdNlbwiWgzOprNT2P6h_XKTJXMVXXqD8Vis33hjzsJRAvT-Fn4w7moO0kKLsMY1J92RzTCbJ39ihdS2wuTGHuQdrtpqw3jcOz2ubnVO_nlXWA1hif7U6tR6T6UU9n9Oix6vjR8RIgz0P2Hfz66odDdHtpiW4hVaPFVGjFyM1m4u7wt2Rzkb2-6HRKkdqfYCG6MkzPbYXdddML3LWr3WE9V99nticu_eMAuHXHcEMdb4jgszw1xfE0cb4njLXG8Sxw3xHFDHL8mjlviuCVujxNvfE0bb2nbM1d0rPGWtYfsaHQwG459t8CHX8DvD_xQ6xgeok50puAopiqQWShTmQ9kmfVFUGYy0zk6GVoaL06FCAqRxwjgwyTKc_z0Eduu6ko9IekBWkYbDmcB_5iqy1WaqCjSMs50GZTqKXtsH-zJuVVxOWkf-e5vjzxjd67xfM5uaXQb6gV80Ea-NEb-AUYzhBo
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Healing+Human+Moderate+and+Large+Traumatic+Tympanic+Membrane+Perforations+Using+Basic+Fibroblast+Growth+Factor%2C+0.3%25+Ofloxacin+Eardrops%2C+and+Gelfoam+Patching&rft.jtitle=Otology+%26+neurotology&rft.au=Lou%2C+Zheng-Cai&rft.au=Lou%2C+Zi-Han&rft.au=Liu%2C+Ya-Chao&rft.au=Chang%2C+Jiang&rft.date=2016-07-01&rft.eissn=1537-4505&rft.volume=37&rft.issue=6&rft.spage=735&rft_id=info:doi/10.1097%2FMAO.0000000000001080&rft_id=info%3Apmid%2F27295381&rft_id=info%3Apmid%2F27295381&rft.externalDocID=27295381